Bristol-Myers Squibb Company (BMY)vsEquinor ASA ADR (EQNR)
BMY
Bristol-Myers Squibb Company
$55.67
-0.87%
HEALTHCARE · Cap: $114.68B
EQNR
Equinor ASA ADR
$36.69
-0.60%
ENERGY · Cap: $91.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Equinor ASA ADR generates 115% more annual revenue ($104.26B vs $48.48B). BMY leads profitability with a 15.0% profit margin vs 5.3%. EQNR appears more attractively valued with a PEG of 0.93. EQNR earns a higher WallStSmart Score of 65/100 (B-).
BMY
Buy60
out of 100
Grade: C+
EQNR
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+31.9%
Fair Value
$87.95
Current Price
$55.67
$32.28 discount
Margin of Safety
+46.5%
Fair Value
$53.41
Current Price
$36.69
$16.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 39 in profit
Strong operational efficiency at 33.0%
Large-cap with strong market position
Attractively priced relative to earnings
Strong operational efficiency at 31.5%
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Earnings expanding 29.2% YoY
Generating 2.1B in free cash flow
Areas to Watch
2.6% revenue growth
Expensive relative to growth rate
Distress zone — elevated risk
Elevated debt levels
5.3% margin — thin
Weak financial health signals
Revenue declined 5.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : BMY
The strongest argument for BMY centers on Return on Equity, Operating Margin, Market Cap.
Bull Case : EQNR
The strongest argument for EQNR centers on Operating Margin, Market Cap, PEG Ratio. PEG of 0.93 suggests the stock is reasonably priced for its growth.
Bear Case : BMY
The primary concerns for BMY are Revenue Growth, PEG Ratio, Altman Z-Score. Debt-to-equity of 2.55 is elevated, increasing financial risk.
Bear Case : EQNR
The primary concerns for EQNR are Profit Margin, Piotroski F-Score, Revenue Growth.
Key Dynamics to Monitor
BMY carries more volatility with a beta of 0.26 — expect wider price swings.
BMY is growing revenue faster at 2.6% — sustainability is the question.
EQNR generates stronger free cash flow (2.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
EQNR scores higher overall (65/100 vs 60/100). BMY offers better value entry with a 31.9% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bristol-Myers Squibb Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Visit Website →Equinor ASA ADR
ENERGY · OIL & GAS INTEGRATED · USA
Equinor ASA, an energy company, is engaged in the exploration, production, transportation, refining and marketing of petroleum and petroleum products and other forms of energy, as well as other companies in Norway and internationally. The company is headquartered in Stavanger, Norway.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?